2[1]Coste J.Screening for viral genomes in blood transfusion.Transfusion Clin Biol,2000,;7:11S
3[2]Burnout T,Radosevich M.Reducing the risk of infection from plasma products:specific preventative strategies.Blood Rev,2000,14(2):94
4[3]Brust S,Duttmann H,Feldner J,et al.Shortening of the diagnonstic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test.J Virol Methods,2000,90(2):153
5[4]Hashida S,Ishikawa S,Nishikata I,et al.Earlier detection of human immunodeficiency virus ype 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays.Clin Diang Lab Immunol,2000,7(6):872
7Bruisten SM,Oudshoorn P,van Swieten P,et al. Stability of HIV-1 RNA in blood during specimen handing and storage prior to amplification by NASBA-QT. J Virol Meth, 1997,67:199.
8Schreiber GB, Bush MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infection. The Retrovirus Epidemiology Donors Study. N Engl J Med, 1996,334:1685.
9Gallarda JL,Dragon E. Blood screening by nucleic acid amplification technology: current issues, furore challenges. Mol Diag,2000,5:11.
10Noeel, L. GAT testing:added value. In:Smit Sibinga C Th, Alters HJ,eds. Risk management in blood transfusion:The virtue of reality. Dordrecht, Kluwer Academic Publishers, 1999:109-117.
